Our finding that NAMPT, NMNAT1, and NMNAT2 labelling decreases in the inner retina with severe disease might limit this NAD synthesis in more severe glaucoma patients, however, these enzymes remain detectable at 32%, 49%, and 46% respectively, supporting the ability to generate NAD even in more diseased retina. This evidence concerns the gene NMNAT1 and glaucoma.